Company Overview - Integer Holdings is a leading global medical device outsource manufacturer with operations across the United States and internationally [6] - The company produces a broad portfolio of medical device components and finished devices, including cardiac rhythm management systems, neuromodulation products, vascular and orthopedic instruments, and customized battery solutions [9] - Integer Holdings serves multinational original equipment manufacturers (OEMs) in the healthcare sector, focusing on markets such as cardiac, neuromodulation, orthopedics, vascular, and advanced surgical devices [9] Financial Performance - As of February 17, 2026, Integer Holdings has a market capitalization of $3.07 billion, with a revenue of $1.83 billion and a net income of $86.90 million for the trailing twelve months (TTM) [4] - The company reported 8% full-year sales growth to $1.85 billion and 21% adjusted EPS growth to $6.40, with adjusted EBITDA reaching $402 million, up 12% year over year [10] - Integer Holdings generated $196 million in operating cash flow for 2025 [10] Recent Developments - On February 17, 2026, Newtyn Management disclosed a new position in Integer Holdings, acquiring 550,000 shares valued at approximately $43.14 million [1][2] - This new position accounts for 4.53% of Newtyn Management's 13F reportable assets under management as of December 31, 2025 [8] - As of the same date, shares of Integer Holdings were priced at $87.66, reflecting a decline of 37.9% over the past year, underperforming the S&P 500 by 49.75 percentage points [8] Debt and Guidance - Integer Holdings has a meaningful debt level of approximately $1.19 billion net, equating to about 3.0 times adjusted EBITDA [11] - Management is guiding for leverage between 2.5 and 3.5 times in 2026, with sales guidance implying flat to slightly down GAAP revenue, while adjusted earnings are expected to remain stable [11] Investment Considerations - The medical device manufacturing sector is characterized as steady, capital-intensive, and deeply embedded in customers' supply chains, making Integer Holdings' new position noteworthy despite its recent stock performance [10] - Long-term investors are encouraged to focus on organic growth, margin expansion, and deleveraging, as a well-executed strategy could lead to compounded growth for the company [12]

The company continued to bask in the afterglow of a double beat in its latest reported quarter.Investors were eager to grab hold of Integer Holdings (ITGR +2.31%) stock on the last trading day of the week. This was on the back of several bullish analyst moves on the company, including a recommendation upgrade. These factors lifted the medical device specialist's stock price by more than 2% on the day. The power of the punditsThose prognosticator adjustments came a day after Integer published its latest earn ...

Key Takeaways ITGR topped Q4 estimates with EPS up 23% and revenues rising 5% year over year.Integer Holdings saw strong C&V growth, but CRM&N and Other Markets faced demand headwinds.ITGR guided 2026 sales flat to down 1%, citing slower adoption of three newer products.Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.76 in the fourth quarter of 2025, which improved 23.1% year over year. The figure surpassed the Zacks Consensus Estimate by 3.5%.The adjustments include ex ...

For the quarter ended December 2025, Integer (ITGR) reported revenue of $472.06 million, up 5% over the same period last year. EPS came in at $1.76, compared to $1.43 in the year-ago quarter.The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $462.63 million. With the consensus EPS estimate being $1.70, the EPS surprise was +3.62%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

Integer (ITGR) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.62%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.68 per share when it actually produced earnings of $1.79, delivering a surprise of +6.55%.Over the last four q ...

Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Company ParticipantsAndrew Senn - Director of Investor RelationsDiron Smith - EVP and CFOConference Call ParticipantsAndrew Cooper - AnalystBrett Fishbin - AnalystJoanne Wuensch - AnalystMatthew O'Brien - AnalystNathan Treybeck - AnalystPayman Khales - AnalystRichard Newitter - AnalystSuraj Kalia - AnalystTravis Steed - AnalystOperatorGood morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporati ...

Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Company ParticipantsAndrew Senn - Director of Investor RelationsDiron Smith - EVP and CFOConference Call ParticipantsAndrew Cooper - AnalystBrett Fishbin - AnalystJoanne Lynch - AnalystMatthew O'Brien - AnalystNathan Treybeck - AnalystPayman Khales - AnalystRichard Newitter - AnalystSuraj Kalia - AnalystTravis Steed - AnalystOperatorGood morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporation ...

Integer (NYSE:ITGR) Q4 2025 Earnings call February 19, 2026 09:00 AM ET Speaker7Good morning, and thank you for standing by. Welcome to Energous, excuse me, Integer Holdings Corporation's fourth quarter 2025 earnings call. My name is Audra, and I will be your conference operator today. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. Please note this call is being recorded. I would now like to turn the conference over to Krist ...

Integer Holdings Corporation (ITGR) Fourth Quarter 2025 Earnings Conference Call February 19, 2026 Presenters and Agenda Today's agenda: Kristen Stewart, CFA Director, Investor Relations CONFIDENTIAL | February 19, 2026 | 2 ITGR: 4Q25 Earnings Conference Call Payman Khales President, Chief Executive Officer Diron Smith Executive Vice President, Chief Financial Officer • Opening Remarks • Strategy Update • Financial Results • Financial Outlook • Wrap-up • Q&A Presentation of Financial Information & Forward-L ...

Financial Performance - Integer Holdings Corporation achieved 8% sales growth and 21% adjusted EPS growth for the full year 2025 compared to 2024[1][4] - In Q4 2025, Cardio & Vascular sales increased 11% to $284 million, while full year sales rose 17% to $1.107 billion[5][21] - Adjusted operating income for 2025 increased by 13% to $321 million, with adjusted net income rising 23% to $226 million[6][19] - Integer Holdings Corporation reported Q4 2025 sales of $472.06 million, a 5.7% increase from $449.50 million in Q4 2024[37] - For the full year 2025, sales reached $1.85 billion, up 8.0% from $1.72 billion in 2024[37] - Gross profit for Q4 2025 was $124,756 thousand, up from $116,796 thousand in Q4 2024, representing a 8.4% increase[38] - Operating income for the year ended December 31, 2025, was $221,264 thousand, compared to $208,238 thousand in 2024, reflecting a 6.4% growth[38] - Net income for 2025 was $102,808 thousand, down from $119,896 thousand in 2024, indicating a decrease of 14.3%[39] - Adjusted net income (Non-GAAP) for 2025 was $272,526 thousand, compared to $224,747 thousand in 2024, reflecting a 21.2% increase[42] Sales and Market Trends - The company expects 2026 sales guidance in the range of $1.826 billion to $1.876 billion, reflecting a slight decline of 1% to an increase of 1% from 2025[9] - Adjusted EPS for 2026 is projected to be between $6.29 and $6.78, indicating a decrease of 2% to an increase of 6% compared to 2025[9] - Cardiac Rhythm Management & Neuromodulation sales decreased 2% to $167 million in Q4 2025, while full year sales increased by 1% to $669 million[13][21] - Other Markets sales fell 13% to $21 million in Q4 2025, with a full year decline of 27% to $78 million[13][21] - Integer anticipates returning to 200 basis points above-market organic sales growth in 2027[4] - The company experienced a total sales growth of 5.0% in Q4 2025 compared to Q4 2024, with organic sales change of 2.0% after adjusting for foreign currency and acquisitions[58] - Cardio & Vascular segment sales grew by 11.3% in Q4 2025, while the Cardiac Rhythm Management & Neuromodulation segment saw a decline of 1.9%[58] Debt and Financial Position - Total debt increased by $195 million to $1.185 billion, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of December 31, 2025[6] - Integer's net total debt was $1.19 billion as of December 31, 2025, compared to $990.15 million in 2024, indicating a 20.1% increase[36] - Total debt increased to $1,185,179,000 as of December 31, 2025, from $990,153,000 in 2024, resulting in a net total debt of $1,190,123,000, up from $954,451,000[61] Shareholder Activities - Integer plans to repurchase approximately $50 million of its common stock as part of an accelerated share repurchase program[8] - The company plans to engage in share repurchase activities, including an Accelerated Share Repurchase (ASR) program[31] Operational Efficiency and Costs - The company incurred $46,681 thousand in debt conversion inducement expense in 2025, which was not present in 2024[39] - The company incurred restructuring and restructuring-related charges of $3,767,000 in Q4 2025, compared to $1,517,000 in Q4 2024, indicating increased costs associated with realignment efforts[54] - The implementation of a new global ERP solution incurred costs of $1,651,000 in 2025, indicating a significant investment in operational efficiency[54] - The company recorded leadership transition costs of $2,400,000 in Q4 2025 and $4,100,000 for the year, reflecting ongoing strategic adjustments[50] Cash Flow and Assets - Cash flows from operating activities for 2025 totaled $196,148 thousand, slightly down from $205,205 thousand in 2024[40] - The company’s total assets increased to $3.41 billion in 2025, compared to $3.08 billion in 2024, reflecting a growth of 10.8%[36] - Current assets rose to $770.10 million in 2025, up from $671.12 million in 2024, marking a 14.8% increase[36] - Integer's cash and cash equivalents decreased to $17.16 million in 2025 from $46.54 million in 2024, a decline of 63.2%[36] - Cash and cash equivalents at the end of 2025 were $17,161 thousand, a decrease from $46,543 thousand at the end of 2024[40] Future Outlook - Adjusted EBITDA for the year is expected to reflect continued growth, supporting the company's strategy to enhance shareholder value[31] - The company anticipates a return to above-market organic sales growth in 2027, driven by new product developments and market expansions[31]